Akcea Therapeutics (NASDAQ:AKCA) and Ionis Pharmaceuticals (NASDAQ:IONS) announced on Tuesday the results for a phase 2 trial featuring AKCEA-ANGPTL3- LRx, a drug candidate developed to combat hypertriglyceridemia. Patients with non-alcoholic fatty liver disease, type 2 diabetes, and hypertriglyceridemia (elevated triglyceride levels) showed significant improvements in their blood work.

A total of 105 patients with one of those three conditions were administered AKCEA-ANGPTL3- LRX via subcutaneous injection for six months. The results found there was a significant reduction in the levels of fasting triglycerides in comparison to the placebo, as well as other lipid indicators such as very-low-density lipoprotein (VLDL-C). The drug was well tolerated among patients, with the most common side effect being a mild reaction where the injection was administered. The full details of this study will be presented at a later medical conference, although it wasn't mentioned which one.

A person holding one of many test tubes, with this one being a test for triglyceride levels.

Image source: Getty Images.

AKCEA-ANGPTL3- LRX was first discovered and developed by Ionis, before being spun off and further developed by Akcea. Ionis still owns a 75% stake in the company, with Novartis choosing not to exercise an option to own a portion of the rights to the drug back in December. 

Further details

Back in October, Akcea announced a licensing agreement with Pfizer, with the former receiving $250 million upfront from the pharmaceutical giant, and half of that amount going to Ionis. The agreement goes on to state that Pfizer will take over developing the drug candidate now that this phase 2 study is finished.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.